Opioid Blister Packs Need Study Before Mandate, Groups Urge
Executive Summary
AAM, Upsher-Smith, APhA, and Cigna tell US FDA that packaging requirement will increase manufacturing and drug costs, create reimbursement hurdles and reduce access to medicines. Daiichi-Sankyo supports agency's proposal.
You may also be interested in...
Opioid 'Data Warehouse' Is Part Of US FDA's New Controlled Substances Program
CDER-based program lead by Marta Sokolowska will also handle benzodiazepine and stimulants activities and consult on relevant application assessments.
FDA Review Modernization Fully Funded
After receiving $25.1m in FY 2019, Congress gave another $1.9m in FY 2020, which appropriators said combined reaches the $27m requested for the FY 2020 budget.
Generics Modernization Effort At US FDA Receives Full Funding Over Two Years
After receiving $25.1m in FY 2019, Congress gave another $1.9m in FY 2020, which appropriators said combined reaches the $27m requested for the FY 2020 budget.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
